title: The PI3K/Akt pathway upregulates Id1 and integrin α4 to enhance recruitment of human ovarian cancer endothelial progenitor cells.
abstract: BACKGROUND
  Endothelial progenitor cells (EPCs) contribute to tumor angiogenesis and growth. We aimed to determine whether inhibitors of differentiation 1 (Id1) were expressed in circulating EPCs of patients with ovarian cancer, whether Id1 could mediate EPCs mobilization and recruitment, and, if so, what underlying signaling pathway it used.
  
  
  METHODS
  Circulating EPCs cultures were from 25 patients with ovarian cancer and 20 healthy control subjects. Id1 and integrin α4 expression were analyzed by real-time reverse transcription-polymerase chain reaction and western blot. EPCs proliferation, migration, and adhesion were detected by MTT, transwell chamber, and EPCs-matrigel adhesion assays. Double-stranded DNA containing the interference sequences were synthesized according to the structure of a pGCSIL-GFP viral vector and then inserted into a linearized vector. Positive clones were identified as lentiviral vectors that expressed human Id1 short hairpin RNA (shRNA).
  
  
  RESULTS
  Id1 and integrin α4 expression were increased in EPCs freshly isolated from ovarian cancer patients compared to those obtained from healthy subjects. siRNA-mediated Id1 downregulation substantially reduced EPCs function and integrin α4 expression. Importantly, Inhibition of PI3K/Akt inhibited Id1 and integrin α4 expression, resulting in the decreasing biological function of EPCs.
  
  
  CONCLUSIONS
  Id1 induced EPCs mobilization and recruitment is mediated chiefly by the PI3K/Akt signaling pathway and is associated with activation of integrin α4.
authors.affiliation: Department of Clinical Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China. nfyyzl@163.com
authors.forename: Yajuan
authors.initials: Y
authors.lastname: Su
authors.forename: Lei
authors.initials: L
authors.lastname: Zheng
authors.forename: Qian
authors.initials: Q
authors.lastname: Wang
authors.forename: Jie
authors.initials: J
authors.lastname: Bao
authors.forename: Zhen
authors.initials: Z
authors.lastname: Cai
authors.forename: Ailan
authors.initials: A
authors.lastname: Liu
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D000293:Adolescent; D000328:Adult; D015153:Blotting, Western; D016022:Case-Control Studies; D002448:Cell Adhesion; D002465:Cell Movement; D049109:Cell Proliferation; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016889:Endometrial Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D042783:Endothelial Cells / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D051798:Inhibitor of Differentiation Protein 1 / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D039441:Integrin alpha4 / Q000378:metabolism*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology*; D010053:Ovary / Q000378:metabolism / Q000473:pathology; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D011379:Prognosis; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D034741:RNA, Small Interfering / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D013234:Stem Cells / Q000378:metabolism* / Q000473:pathology; D015854:Up-Regulation; D055815:Young Adult
chemical_list: C497453:ID1 protein, human; D051798:Inhibitor of Differentiation Protein 1; D012333:RNA, Messenger; D034741:RNA, Small Interfering; D039441:Integrin alpha4; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt
references.citation: Science. 2006 Sep 22;313(5794):1785-7
references.pmid: 16990548
references.citation: Science. 2008 Jan 11;319(5860):195-8
references.pmid: 18187653
references.citation: Br J Cancer. 2004 Dec 13;91(12):2042-7
references.pmid: 15599381
references.citation: Prog Cardiovasc Dis. 2007 May-Jun;49(6):421-9
references.pmid: 17498522
references.citation: Nat Med. 2001 Nov;7(11):1194-201
references.pmid: 11689883
references.citation: BMC Cancer. 2009 Dec 10;9:430
references.pmid: 20003244
references.citation: Cancer Res. 2006 Jul 15;66(14):7341-7
references.pmid: 16849585
references.citation: Blood. 2006 Aug 1;108(3):915-21
references.pmid: 16861344
references.citation: In Vivo. 2008 Nov-Dec;22(6):831-6
references.pmid: 19181016
references.citation: Ann Oncol. 2003 Jul;14(7):1086-93
references.pmid: 12853351
references.citation: Oncogene. 2001 Dec 20;20(58):8334-41
references.pmid: 11840326
references.citation: FASEB J. 2006 Jul;20(9):1495-7
references.pmid: 16754748
references.citation: PLoS One. 2007 Dec 19;2(12):e1338
references.pmid: 18092003
references.citation: Nat Rev Cancer. 2006 Nov;6(11):835-45
references.pmid: 17036040
references.citation: Cancer Res. 2006 Nov 15;66(22):10870-7
references.pmid: 17108123
references.citation: J Biol Chem. 2008 Aug 15;283(33):22410-6
references.pmid: 18556654
references.citation: Adv Cancer Res. 2004;92:81-94
references.pmid: 15530557
references.citation: Regen Med. 2008 Nov;3(6):863-76
references.pmid: 18947309
references.citation: Nature. 1999 Oct 14;401(6754):670-7
references.pmid: 10537105
references.citation: Nat Clin Pract Oncol. 2008 Apr;5(4):194-204
references.pmid: 18268546
references.citation: J Clin Invest. 2006 Mar;116(3):652-62
references.pmid: 16498499